Design and rationale of the HD PCI trial: A cluster randomized crossover trial of higher vs. lower dose heparin for elective percutaneous coronary intervention
Authors:
Open Access
- 22 December 2025
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 294, 107330
Abstract
No abstract availableKeywords
Funding Information
- Population Health Research Institute
This publication has 19 references indexed in Scilit:
- Comparative Trends in Percutaneous Coronary Intervention in Japan and the United States, 2013 to 2017JACC, 2020
- A tutorial on sample size calculation for multiple-period cluster randomized parallel, cross-over and stepped-wedge trials using the Shiny CRT CalculatorInternational Journal of Epidemiology, 2020
- Bivalirudin versus Heparin Monotherapy in Myocardial InfarctionNew England Journal of Medicine, 2017
- Anticoagulation in coronary interventionEuropean Heart Journal, 2016
- Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized TrialJAMA, 2010
- Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary InterventionNew England Journal of Medicine, 2008
- Sample size calculation for cluster randomized cross‐over trialsStatistics in Medicine, 2008
- Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary InterventionNew England Journal of Medicine, 2006
- A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in OntarioAmerican Heart Journal, 2002
- Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction AnginaNew England Journal of Medicine, 1995